We encourage authors to provide detailed information within their submission to facilitate the interpretation and replication of experiments. Authors can upload supporting documentation to indicate the use of appropriate reporting guidelines for health-related
Sample-size estimation
• You should state whether an appropriate sample size was computed when the study was being designed • You should state the statistical method of sample size computation and any required assumptions • If no explicit power analysis was used, you should describe how you decided what sample (replicate) size (number) to use Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission: Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:
Replicates
We used at least three biological replicates for each group (3WT vs 3KO). This number of replicates is generally used for RNA-seq in tissues collected from inbred mice, since a low biological and technical variability among the samples is expected. To test the variability in our samples we performed unsupervised clustering (Pearson correlation) and were able to confirm the identity of the tissues, by showing that replicates of the same tissue clustered together. This, result implies a low biological and technical variability across the samples which supports our choice of at least 3 biological replicates.
In addition, for validation of the dysregulated genes observed in the double deletion we use independently generated single KO mouse strains (2 or 3 replicates per group). Each RNA-seq experiment was performed once. In the manuscript we use biological replicates, defined as tissue derived from different individuals, as detailed in the Figures, Figure legends and Material and Methods. We did not conduct technical replicates in this study.
To determine whether the deletion of Firre, Dxz4 or Firre-Dxz4 impact random or imprinted X chromosome inactivation, we collected embryonic day 12.5 brains, placentas and visceral yolk sac from reciprocal F1 crosses between the deletion strains and CAST/EiJ. For the brain and the placenta, we collected samples for all three strains from the forward cross (3 males and 3 females for WT and maternal deletion) and reverse cross (3 females for WT and paternal deletion). For the placenta DKO we added an additional replicate of the maternal and paternal deletion. In addition, we collected visceral yolk sac samples from the DKO forward cross (3 females WT and maternal deletion) and reverse cross (3 females WT and paternal deletion).
Moreover, to test whether DNA methylation levels are altered in the absence of Firre and Dxz4 on either Xa or Xi, we collected placentas from the DKO forward cross (1 female WT and 2 maternal deletion) and reverse cross (2 females WT and 2 paternal deletion) to perform reduced representation bisulfite sequencing (RRBS) sequencing.
For the DKO adult bodymap, we collected the spleen, brain, kidney, heart, lung and liver from 6 weeks old female mice carrying a homozygous double deletion (4 WT and 4 DKO replicates). To validate and classify the dysregulated genes form the DKO, we collected liver and spleen from independent generated female SKO strains (Firre 3 SKO and Dxz4 2 SKO replicates). To test whether the molecular phenotype observed in the female spleen can be uncoupled form X inactivation, we collected 6 weeks old spleens from DKO males (2 WT and 2 DKO replicates).
We displayed outliers in the boxplot figures.
Sequence data and alignments have been submitted to the Gene Expression Omnibus (GEO) database under accession code GSE127554. 
Statistical reporting
• Statistical analysis methods should be described and justified • Raw data should be presented in figures whenever informative to do so (typically when N per group is less than 10) • For each experiment, you should identify the statistical tests used, exact values of N, definitions of center, methods of multiple test correction, and dispersion and precision measures (e.g., mean, median, SD, SEM, confidence intervals; and, for the major substantive results, a measure of effect size (e.g., Pearson's r, Cohen's d) • Report exact p-values wherever possible alongside the summary statistics and 95% confidence intervals. These should be reported for all key questions and not only when the p-value is less than 0.05.
Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:
(For large datasets, or papers with a very large number of statistical tests, you may upload a single table file with tests, Ns, etc., with reference to sections in the manuscript.)
Group allocation
• Indicate how samples were allocated into experimental groups (in the case of clinical studies, please specify allocation to treatment method); if randomization was used, please also state if restricted randomization was applied • Indicate if masking was used during group allocation, data collection and/or data analysis Please outline where this information can be found within the submission (e.g., sections or figure legends), or explain why this information doesn't apply to your submission:
Additional data files ("source data") • We encourage you to upload relevant additional data files, such as numerical data that are represented as a graph in a figure, or as a summary table • Where provided, these should be in the most useful format, and they can be Source data has been provided, including the processed data and R scripts for the figure generation.
Sequence data and alignments have been submitted to the Gene Expression Omnibus (GEO) database under accession code GSE127554. To review GEO accession GSE127554: Go to https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE127554 Enter token mfcvkggovjujfkt into the box
